This clinical trial studies positron emission tomography (PET) imaging utilizing 18F-(2S,4R)4-fluoroglutamine, a glutamic acid derivative, to image patients with Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules. \[18F\]Fluoroglutamine PET may provide additional information that help diagnose lung cancer.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
30
Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT
Xinhua Hospital
Shanghai, Shanghai Municipality, China
RECRUITINGDiagnosing and Staging ability of 4-[18F]Fluoroglutamine PET/CT in lung cancer
Sensitivity, specificity, diagnostic accuracy of 4-\[18F\]Fluoroglutamine and 18F-FDG PET/CT will be compared using paired t-test or Krusal-Wallis test.
Time frame: up to three years
Incidence of Treatment-Emergent Adverse Events
The evaluation of the Incidence of Treatment-Emergent Adverse Events starts from the day of F-Gln examination until 30 days later; Treatment-Emergent Adverse Events are evaluated according to version 4.03 CTC-AE criteria.
Time frame: up to 30 days after the F-Gln imaging
ASCT2 expression levels in tissue samples
Wilcoxon rank-sum or Kruskal-Wallis tests will be applied for the group comparisons of IHC staining(ASCT2)
Time frame: up to three years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.